Please Wait
Applying Filters...
menu
    • menu
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    An Enquiry

    Menu

    Nizubaglustat

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Azafaros Publishes Nizubaglustat Data for GM2 Gangliosidosis
    Azafaros Publishes Nizubaglustat Data for GM2 Gangliosidosis

    25 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260224958744/en/Azafaros-Announces-Publication-of-Preclinical-Efficacy-Data-with-Nizubaglustat-in-GM2-Gangliosidosis

    BUSINESSWIRE
    25 Feb 2026
    Share Share
    Azafaros Presents Nizubaglustat Data At Worldsymposium 2026
    Azafaros Presents Nizubaglustat Data At Worldsymposium 2026

    22 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260121361664/en/Azafaros-Announces-Key-Scientific-Oral-and-Poster-Presentations-on-Nizubaglustat-Accepted-for-WORLDSymposium-2026

    BUSINESSWIRE
    22 Jan 2026
    Share Share
    Azafaros to Present at J.P. Morgan Healthcare Conference
    Azafaros to Present at J.P. Morgan Healthcare Conference

    09 Jan 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250108672251/en

    BUSINESSWIRE
    09 Jan 2025
    Share Share
    Azafaros Gets Regulatory Clearance For 2025 Global Phase 3 Studies
    Azafaros Gets Regulatory Clearance For 2025 Global Phase 3 Studies

    08 Jan 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250107508677/en

    BUSINESSWIRE
    08 Jan 2025
    Share Share
    Positive Nizubaglustat Phase 2 Data Presented For NPC And GM2
    Positive Nizubaglustat Phase 2 Data Presented For NPC And GM2

    10 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240910536439/en

    BUSINESSWIRE
    10 Sep 2024
    Share Share
    Azafaros Reports Positive Phase 2 Data For Nizubaglustat In GM2 And NPC
    Azafaros Reports Positive Phase 2 Data For Nizubaglustat In GM2 And NPC

    16 Jul 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240619007436/en

    BUSINESSWIRE
    16 Jul 2024
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.